CN102327301A - Application of Japanese alder to preparation of medicaments for preventing and treating osteoporosis - Google Patents
Application of Japanese alder to preparation of medicaments for preventing and treating osteoporosis Download PDFInfo
- Publication number
- CN102327301A CN102327301A CN201110288023A CN201110288023A CN102327301A CN 102327301 A CN102327301 A CN 102327301A CN 201110288023 A CN201110288023 A CN 201110288023A CN 201110288023 A CN201110288023 A CN 201110288023A CN 102327301 A CN102327301 A CN 102327301A
- Authority
- CN
- China
- Prior art keywords
- osteoporosis
- group
- application
- preventing
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses application of Japanese alder to the preparation of medicaments for preventing and treating osteoporosis. In the application, aiming at the pathogenesis and clinical symptoms of osteoporosis, a Chinese medicinal material, namely the Japanese alder serving as a raw material has the effect of increasing bone density so as to fulfill the aim of preventing and treating osteoporosis.
Description
Technical field
The present invention relates to the medicinal application frontier, be specifically related to the application of Folium Et Cacumen Alni Japonicae in preparation control medicine for treating osteoporosis.
Background technology
(Osteoporosis is because unit volume internal skeleton tissue mass reduces, the bone fine structure destroys OP) to osteoporosis, causes the fragility of bone to increase, the normal a kind of chronic general skeletal diseases that is prone to take place osteodynia even fracture.Can be divided into two big types of constitutional and Secondary cases, primary osteoporosis can be divided into senile osteoporosis and postmenopausal osteoporosis again.Osteoporosis is a kind of common senile disease, this disease and complication thereof fracture, cause pain, disable, early death human health is constituted greatly threaten, how to prevent and treat has become important public health problem.
The danger that prevents or reduce further bone loss, bone mass increasing and reduction to fracture is the main purpose of clinical treatment osteoporosis.The Prevention and Treatment of Osteoporosis disease drug has a variety of; Can be divided into two types according to mechanism of action; The one, suppress the bone resorption medicine, mainly contain estrogen (estrogen), calcitonin (calcitonin), diphosphonates (bisphosphonates), ipriflavone (ipriflavone) etc.; The 2nd, short bone formation medicine mainly contains bone mineralizer (calcium salt, vitamin D and derivant thereof), androgens (androgen), growth hormone (GH), fluoride (fluoride), protein anabolic hormone (anabolic steroids) etc.
Folium Et Cacumen Alni Japonicae is browse and the bark of Betulaceae plant Folium Et Cacumen Alni Japonicae, contains multiple triterpenoids such as lupenone, α-Amyrin, β-Amyrin, glut-5-en-3, taraxerol, betulic acid; Nature and flavor are bitter, puckery, cold, and effect is a resolving heat and reducing pathogenic fire, often is applied in hemostasis.Do not see treatment osteoporosis report is arranged.
Summary of the invention
The objective of the invention is deficiency, the new purposes of alder in preparation control medicine for treating osteoporosis is provided based on the prior art existence.
Above-mentioned purpose of the present invention is achieved through following technical scheme:
Folium Et Cacumen Alni Japonicae is browse and the bark of Betulaceae plant Folium Et Cacumen Alni Japonicae, and nature and flavor are bitter, puckery, cool.Adopt alder or its extract as raw material, single with or with other Chinese traditional medicine composition with prevention and the effect of treatment osteoporosis routinely formulation method can be prepared into oral any formulation.Wherein other medicines with prevention and the effect of treatment osteoporosis comprise one or both in Herba Epimedii, the Fructus Psoraleae.
Particularly when addition was 10 ~ 40g/kg, effect of drugs was best to Folium Et Cacumen Alni Japonicae according to the invention.
Compared with prior art, the present invention has following beneficial effect:
The present invention is directed to osteoporotic pathogenesis and clinical symptoms, play bone density improving, improve serum calcium, phosphorus content effect in the body, thereby reach the purpose of Prevention and Treatment of Osteoporosis.
The specific embodiment
Come further to explain the present invention below in conjunction with embodiment, but embodiment does not do any type of qualification to the present invention.
Embodiment 1
1. experimental technique:
The SD male rat at 60 3 monthly ages is divided into 5 groups at random, and promptly matched group, model group, administration high dose group and middle dose groups, low dosage are three groups.Every group 12.All the other four groups of rat skin lower injection first are sprinkled Buddhist nun 3.5mg/kg except that matched group, every day 1 subcutaneous injection, continuous 60 days.The administration group is irritated stomach simultaneously and is given medicine of the present invention, and Folium Et Cacumen Alni Japonicae decocting liquid adopts conventional decocting method preparation, and the simmer down to respective concentration, and decocting liquid various dose group comprises low dose group (10g/kg), middle dose groups (20g/kg), high dose group (40g/kg); Gastric infusion is respectively organized in medication, and all the other each groups are irritated the normal saline of clothes equivalent, experiment successive administration totally 60 days.Measure bone density (BMD) after 60 days, serum calcium, serum paraoxonase and serum osteocalcin (BGP) level.
2. experimental result
The experiments result of laboratory animal sees the following form 1 after the administration.
Table 1 each item desired value relatively
( 
)
* representative is compared with matched group
P<0.05; The * representative is compared with model group,
P<0.05
Above-mentioned experimental result shows: model group and matched group compare, all significantly reductions of bone density (
P<0.05), show that experimental animal model prepares successfully; Each dose groups serum calcium of administration, phosphorus content, whole body bone density content all raise to some extent, with model group relatively, difference have the significance meaning (
P<0.05), explain medicine of the present invention can control agent in content of mineral substances, bone density improving has certain preventive and therapeutic effect to osteoporosis.
Embodiment 2
1 experimental technique
The SD male rat at 60 3 monthly ages is divided into 5 groups at random, and promptly matched group, model group, administration high dose group and middle dose groups, low dosage are three groups, 12 every group.All the other four groups of rat skin lower injection first are sprinkled Buddhist nun 3.5mg/kg except that matched group, every day 1 subcutaneous injection, continuous 60 days.
What the administration group irritated simultaneously that stomach gives medicine of the present invention and Fructus Psoraleae fries in shallow oil the water extract altogether; Decocting liquid adopts conventional decocting method preparation, and the simmer down to respective concentration, and decocting liquid various dose group comprises low dose group (10g/kg); Middle dose groups (20g/kg), high dose group (40g/kg); Gastric infusion is respectively organized in medication, and all the other each groups are irritated the normal saline of clothes equivalent, experiment successive administration totally 60 days.Measure bone density (BMD) after 60 days, serum osteocalcin (BGP) and serum calcium, phosphorus level.
2 experimental results
The experiments result of laboratory animal sees the following form 2 after the administration.
Table 2 each item desired value relatively
( 
)
* representative is compared with matched group
P<0.05; The * representative is compared with model group,
P<0.05
Above-mentioned experimental result shows: model group and matched group compare, all significantly reductions of bone density (
P<0.05), show that experimental animal model prepares successfully; Each dose groups serum calcium of administration, phosphorus content, whole body bone density content all raise to some extent, with model group relatively, difference have the significance meaning (
P<0.05), explain medicine of the present invention can control agent in content of mineral substances, bone density improving has certain preventive and therapeutic effect to osteoporosis.
Embodiment 3
1 experimental technique
The SD male rat at 60 3 monthly ages is divided into 5 groups at random, and promptly matched group, model group, administration high dose group and middle dose groups, low dosage are three groups, 12 every group.All the other four groups of rat skin lower injection first are sprinkled Buddhist nun 3.5mg/kg except that matched group, every day 1 subcutaneous injection, continuous 60 days.
What the administration group irritated simultaneously that stomach gives medicine of the present invention and Radix Puerariae, Herba Epimedii fries in shallow oil the water extract altogether; Decocting liquid adopts conventional decocting method preparation, and the simmer down to respective concentration, and decocting liquid various dose group comprises low dose group (10g/kg); Middle dose groups (20g/kg), high dose group (40g/kg); Gastric infusion is respectively organized in medication, and all the other each groups are irritated the normal saline of clothes equivalent, experiment successive administration totally 60 days.Measure bone density (BMD) after 60 days, serum osteocalcin (BGP) and serum calcium, phosphorus level.
2 experimental results
The experiments result of laboratory animal sees the following form 3 after the administration.
Table 3 each item desired value relatively
( 
)
* representative is compared with matched group
P<0.05; The * representative is compared with model group,
P<0.05
Above-mentioned experimental result shows: model group and matched group compare, all significantly reductions of bone density (
P<0.05), show that experimental animal model prepares successfully; Each dose groups serum calcium of administration, phosphorus content, whole body bone density content all raise to some extent, with model group relatively, difference have the significance meaning (
P<0.05), explain medicine of the present invention can control agent in content of mineral substances, bone density improving has certain preventive and therapeutic effect to osteoporosis.
Claims (3)
1. the application of Folium Et Cacumen Alni Japonicae in preparation control medicine for treating osteoporosis.
2. application according to claim 1, the addition that it is characterized in that said Folium Et Cacumen Alni Japonicae is 10-40g/kg.
3. according to claim 1 or 2 said application, it is characterized in that said medicine is an oral formulations.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110288023A CN102327301A (en) | 2011-09-26 | 2011-09-26 | Application of Japanese alder to preparation of medicaments for preventing and treating osteoporosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110288023A CN102327301A (en) | 2011-09-26 | 2011-09-26 | Application of Japanese alder to preparation of medicaments for preventing and treating osteoporosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102327301A true CN102327301A (en) | 2012-01-25 |
Family
ID=45479432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110288023A Pending CN102327301A (en) | 2011-09-26 | 2011-09-26 | Application of Japanese alder to preparation of medicaments for preventing and treating osteoporosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102327301A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101522183A (en) * | 2006-08-02 | 2009-09-02 | 秋久俊博 | Pharmaceutical composition for prevention and/or treatment of bone disease, functional food or health food comprising the composition, and pharmaceutical preparation comprising the composition as acti |
-
2011
- 2011-09-26 CN CN201110288023A patent/CN102327301A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101522183A (en) * | 2006-08-02 | 2009-09-02 | 秋久俊博 | Pharmaceutical composition for prevention and/or treatment of bone disease, functional food or health food comprising the composition, and pharmaceutical preparation comprising the composition as acti |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105012711B (en) | It is a kind of to be used to alleviate composition of physical fatigue and tonifying kidney and strengthening yang and preparation method thereof | |
| CN101843694B (en) | Chinese medicament for treating chronic hepatitis | |
| CN1268370C (en) | Capsules for nourishing kidney and strengthening yang | |
| CN103071060B (en) | Traditional Chinese medicine preparation for treating ankylosing spondylitis | |
| CN101953877A (en) | Medicinal composition for treating osteoporosis | |
| CN102240345A (en) | Compound Chinese herbal medicine preparation for preventing and treating Newcastle disease | |
| CN104758451A (en) | Traditional Chinese medicine composite for treating gout | |
| CN102106999A (en) | Chinese medicinal compound preparation for treating dysphagia due to stroke and preparation method thereof | |
| CN102614365B (en) | Traditional Chinese medical composition for treatment of breast tumor | |
| CN102379967A (en) | Traditional Chinese medicine for treating diabetic retinopathy | |
| CN101474189A (en) | Halometasone medicinal preparation and preparation method | |
| CN102327301A (en) | Application of Japanese alder to preparation of medicaments for preventing and treating osteoporosis | |
| CN101181441B (en) | Medicament for curing gonad progeria as well as preparation technique thereof | |
| CN105362382A (en) | Traditional Chinese medicine composition for treating recurrent oral ulcer and application thereof | |
| CN102327318A (en) | Application of rubescensine in preparation of drug for preventing and treating osteoporosis | |
| CN102697912A (en) | Traditional Chinese medicament for treating epistaxis | |
| CN102716448A (en) | Chinese patent medicine and TCM decoction capable of effectively curing nausea and vomiting | |
| CN115120690B (en) | Traditional Chinese medicine composition for treating precocious puberty and application thereof | |
| CN101502597A (en) | Medicament for treating stomachache and preparation method thereof | |
| CN101011512A (en) | Medicine for treating digestive tract tumour and its preparing process | |
| CN102416061A (en) | Compound oil-in-water type largehead atractylodes rhizome oil nanoemulsion composition and preparation method thereof | |
| CN102908562B (en) | Traditional Chinese medicine combination for treating breast diseases and preparation method thereof | |
| CN102755378B (en) | Traditional Chinese medicine composition for preventing and treating osteoporosis and preparation method thereof | |
| CN104189693A (en) | Traditional Chinese medicine composition for treating posemenopausal osteoporosis | |
| CN100364586C (en) | Medicine for treating digestive tract tumor and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120125 |